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Abstract
Sorafenib is an oral multikinase inhibitor with anti-proliferative and anti-angiogenic effects and is used worldwide
for the treatment of advanced or metastatic hepatocellular carcinoma (HCC). While the significant survival benefit of
sorafenib in patients with advanced HCC was demonstrated, various treatment-related adverse events might happen. Of
them, the incidence of drug-related severe liver dysfunction rarely occurs (<1 %) but is one of the serious adverse events
by sorafenib. The authors highlight the case of a 71-year-old man with metastatic HCC with sorafenib-related fatal liver
dysfunction (T-Bil 28.6 mg/dL, AST 1611 IU/L, ALT 1098 IU/L) 2 months later even without either intrahepatic viable HCC
or hepatitis B virus (HBV) reactivation. Then, the liver dysfunction was improved following aggressive treatment using
hyperbaric oxygen. A liver biopsy demonstrated cholestasis, degeneration, and necrosis in hepatocytes with lymphocyte
infiltration. Thus, sorafenib rarely can induce liver dysfunction characterized by cholestatic and hepatocellular injury types,
and it could be a fatal event. Clinicians should pay attention to any increase in the liver enzymes in these patients.
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Background
Sorafenib is an oral multikinase inhibitor and additionally
inhibits VEGF and PDGF and affect as an anti-angiogenic
agent, so it is worldwidely used for the treatment of ad-
vanced or metastatic hepatocellular carcinoma (HCC).
While the two phase-3 randomized double-blind con-
trolled trials (the Sorafenib Hepatocellular Carcinoma As-
sessment Randomized Protocol (SHARP) and Asia-Pacific
trials) demonstrated statistically significant improvement
in overall survival and in time to disease progression in pa-
tients with advanced HCC, the overall incidence of
treatment-emergent (drug- or non-drug related) adverse
events of any grades has been reported to be up to
81.9~97.2 % [1, 2]. The adverse events of higher frequency
in sorafenib were hand-foot skin reaction, diarrhea, general
fatigue, and anorexia; each frequency of which were re-
ported to be 21–67, 11–39, 22–30, and 14–16 %. Of all the
adverse events, the incidence of drug-related severe ad-
verse events was 8.7 %, and liver dysfunction is rare but
one of the major serious adverse events by sorafenib. Here,
we showed the successfully treated case with fatal liver dys-
function induced by sorafenib.
Case presentation
A 77-year-old man, with well-controlled hepatitis B virus
(HBV) by entecavir (HBsAg positive, HBsAb negative,
HBcAb positive, HBeAg negative, and undetectable
HBV-DNA), was diagnosed with a primary HCC and
was treated with radiofrequency ablation (RFA) in January
2010 at the previous hospital. Ten months later, he was
admitted to our hospital because of the intrahepatic recur-
rences and then treated with RFA and with partial hepa-
tectomy. One year later, he had a recurrence at the needle
site of RFA on the chest wall and local resection was
performed. However, he showed multiple and bilateral
lung metastases with local recurrence at the chest wall,
whereas there was no viable lesion in the liver. At that
time, liver function was categorized as Child-Pugh class A
with normal range of blood counts, electrolytes, and renal
functions. Sorafenib was introduced 400 mg twice a day
(total 800 mg/day), and there was no significant adverse
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event 1 week after the administration. Just after 1 month,
when we checked, he is in a good general condition only
with slight hand rubefaction that does not influence the
treatment continuation and his laboratory data are with-
out unexpected values (the serum total bilirubin 1.4 mg/dl,
AST 33 IU/L, ALT 24 IU/L); he had general fatigue and
appetite loss, and those symptoms gradually worsened
despite improvement of the skin reaction. Two months
after the induction of sorafenib, the symptoms aggressively
worsened, and the laboratory data demonstrated signifi-
cantly worsened liver functions in the serum bilirubin value
(total bilirubin 28.6 mg/dl, direct bilirubin 20.4 mg/dl),
transaminase values (AST 1611 IU/L, ALT 1098 IU/L),
and other liver enzymes (Table 1), without significant evi-
dence of HBV reactivation. By computed tomography,
there is no significant finding such as intra- and extra-
biliary duct dilatation and intrahepatic recurrence. There-
fore, the fatal liver dysfunction was diagnosed due to
sorafenib-related adverse event. We stopped the intake of
sorafenib and treated with stronger Neo-Minophagen C
and ursodeoxycholic acid. While serum transaminase
values decreased in response to the above treatments, the
serum bilirubin level did not change. As a next therapeutic
approach, we started hyperbaric oxygen therapy (HBOT)
every business day from day 8. HBOT was provided with a
monoplace hyperbaric chamber. He was accommodated
for about an hour and a half in the chamber, where the
ambient pressure with pure oxygen increased two times
higher than the local atmospheric pressure in 10 to 15 min;
it was maintained for 60 min and was relieved back to the
atmospheric pressure gradually in the same or more time
spent than the increasing time. Thereafter, the serum biliru-
bin level started to decrease depending on the number of
times of HBOT, and he could sustain himself with oral take
(Fig. 1). Interestingly, the serum bilirubin levels failed to de-
crease during the weekend without HBOT. For example,
while gradual decrease of the serum total bilirubin level
was observed in the interval only on weekdays between
days 15 (18.9 mg/dl) and 18 (17.4 mg/dl), there is no
change of the bilirubin level in the interval including a
weekend between days 18 and 22 (17.7 mg/dl). This ten-
dency was observed during the prominent hyperbilirubine-
mia. A liver biopsy was performed, and the microscopic
findings demonstrated cholestasis, degeneration, and necro-
sis in hepatocytes with lymphocyte infiltration (Fig. 2). On
day 43 from the start of treatment, although a phenobar-
bital was administered in addition to HBOT in anticipation
of further improvement in bilirubin level, an additional
phenobarbital treatment seemed to be not effective. After
2 months of treatment, serum bilirubin level was around
3 mg/dl and he was discharged and restarted to treat HCC
with tegafur/uracil leucovorin, but as progression of the
lung metastases, he died 1 year after discharge.
Conclusions
Here, we showed the metastatic HCC case with fatal
liver dysfunction induced by sorafenib which successfully
improved following aggressive treatment using HBOT.
The presented case revealed a conjugated hyperbilirubi-
nemia and liver injury even without intrahepatic viable
HCC. Indeed, liver biopsy proved the cholestasis and
liver damage in hepatocytes with lymphocyte infiltration
Table 1 Laboratory data on admission
Total-bilirubin 28.6 mg/dl α-fetoprotein (AFP) 98.2 ng/ml PT 16.3 s
D-Bilirubin 20.4 mg/dl AFP-L3 20.1 % PT 60 %
Albumin 3.3 g/dl PIVKA-II 876 mAU/ml PT 1.47
ALT 1098 U/l CEA 3 ng/ml APTT 39.4 s
AST 1611 U/l APTT 67 %
Ammonia 29 μg/dl White blood cell 4300/μl
Bile acid 175 μmol/l Neutrocytes 68 %
γ-GTP 136 mg/dl Hemoglobin 12.7 g/dl
LDH 70 U/l Platelet counts 7.3 × 103/μl
ALP 606 U/l Child-Pugh score 8 (grade B)






ALT alanine transaminase, AST aspartate aminotransferase, γ-GTP γ-glutamyl transpeptidase, LDH lactate dehydrogenase, ALP alkaline phosphatase, CRP C-reactive
protein, BUN blood urea nitrogen, PT prothrombin time, PT-INR prothrombin time-international normalized ratio, PIVKA-II des-γ-carboxy prothrombin, CEA
carcinoembryonic antigen
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due to sorafenib intakes. In addition, the fact that HBOT
was successful in the presented case suggests the type of
liver injury induced by sorafenib. The benefits of HBOT
against cholestasis have been reported in vivo [3, 4], and
the mechanism of the therapeutic effect of HBOT to
liver injury is reported to consist of hepatoprotection
associated with anti-oxidative potential and promotion
of liver regeneration [5]. Thus, sorafenib-induced liver
dysfunction may be characterized by cholestasis and cell
deaths in hepatocytes with inflammatory cell infiltration.
The most of sorafenib-associated adverse effects are
mild to moderate and tolerable [2, 6]. On the other
hand, unexpected and serious toxicities including liver
injury have also been reported. In the many clinical set-
tings, it is difficult to judge whether liver injury is caused
by drug toxicity or disease progression in patients with
HCC. Fortunately in this case, there was no viable HCC
in the liver, and no evidence of reactivation of HBV.
These backgrounds greatly helped to diagnose the liver
dysfunction as a sorafenib-induced liver injury. In the
phase I study of sorafenib for patients with advanced, re-
fractory solid tumors, steady-state plasma concentrations
were reached within 7 days by twice-daily oral intake [7].
In this study, transient grade 3 elevation of conjugated
bilirubin, without concomitant elevation of other hepatic
enzymes, was reported in 3 (4 %) of 69 patients, and it
was described that the elevation of bilirubin appeared in-
dependently of the dose level and occurred on day 3
after the first application and resolved spontaneously by
day 5 [7]. In renal cell carcinoma patients, sorafenib-
related serious adverse event was found at 10.7 %. Of
them, the most frequently occurring drug-related serious
Fig. 1 Time course of treatment and improvement of the liver dysfunction. AST aspartate aminotransferase, ALT alanine aminotransferase, T-Bil total bilirubin,
D-Bil direct bilirubin, UDCA ursodeoxycholic acid, HBOT hyperbaric oxygen therapy, SNMC stronger neo-minophagen C
A B
Fig. 2 Pathological findings of sorafenib-induced liver dysfunction revealed by needle biopsy. a There are fibrous thickening in Glisson’s capsules,
moderate P-P bridging fibrosis, piecemeal necrosis, and ridging necrosis in part. b There are moderate hepatocytic degeneration and necrosis,
lymphocytic infilterate to Glisson’s cupsule, hepatocytic balooning, and cholestasis in hepatocyte
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treatment-emergent adverse events were liver dysfunc-
tion, aspartate aminotransferase elevation, and alanine
aminotransferase elevation, each of which was reported
at 2.3 % [8]. In advanced HCC, the difference of sorafe-
nib pharmacokinetics between Child-Pugh A and B pa-
tients were not considered clinically significant. As a
mechanism of sorafenib-induced liver injury, metabolic
dysfunction has been reported [9]. Sorafenib requires
glucuronidation catalyzed by uridine diphosphate glucu-
ronosyltransferase (UGT) 1A9 of oxidized sorafenib me-
tabolites formed through cytochrome P450 (CYP) 3A4
metabolism. For example, sorafenib exposure was reduced
by an average 37 % with concomitant administration of
the CYP3A4 inducer rifampicin (rifampin); sorafenib con-
centrations may also be decreased by the other CYP3A4
inducers [9]. These enzymes show phenotypic variability
based on polymorphism, suggesting sorafnib metabolism
may be related with polymorphisms of the above enzymes,
though the polymorphism in the present case were un-
examined. Similarly, sorafenib inhibits UGT1A1 bilirubin
conjugation and phenotypically induce hyperbilirubinemia
in patients with Gilbert’s syndrome [10]. In this case, pro-
longed hyperbilirubinemia was so outstanding, and histo-
logically, cholestasis is not in the biliary tract but mainly
in hepatocyte that sorafenib might have inhibit the intra-
cellular process of bilirubin conjugation. In future investi-
gations, the exploration of polymorphism in some
enzymes such as CYP3A4 and UGT1A9 may be useful to
predict the sorafnib-induced liver dysfunction.
Sorafenib rarely can induce liver dysfunction charac-
terized by cholestatic and hepatocellular injury types,
and it could be a fatal event. We advocate appropriate
liver function surveillance in patients with sorafenib, and
the presented HBOT was effective for sorafenib-induced
cholestasis.
Consent
Written informed consent was obtained from the patient
for publication of this case report and any accompanying
images.
Abbreviations
CYP: cytochrome P450; HBV: hepatitis B virus; HCC: hepatocellular carcinoma;
RFA: radiofrequency ablation; UGT1A9: uridine diphosphate
glucuronosyltransferase 1A9.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
KD, HH, HN, KI, and TB underwent the operation. HH, TB, and HB determined
the treatment plan. All the authors including SA, DH, AC, and TI made a round
of visits after the operation. All the authors read and approved the final
manuscript.
Received: 29 March 2015 Accepted: 7 January 2016
References
1. Rimassa L, Santoro A. Sorafenib therapy in advanced hepatocellular
carcinoma: the SHARP trial. Expert Rev Anticancer Ther. 2009;9(6):739–45.
2. Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S, Kim JS, et al. Efficacy and safety
of sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 2009;10(1):25–34.
3. Ayvaz S, Kanter M, Aksu B, Sahin SH, Uzun H, Erboga M, et al. The effects
of hyperbaric oxygen application against cholestatic oxidative stress
and hepatic damage after bile duct ligation in rats. J Surg Res.
2013;183(1):146–55.
4. Idetsu A, Suehiro T, Okada K, Shimura T, Kuwano H. Hyperbaric oxygenation
promotes regeneration of biliary cells and improves cholestasis in rats.
World J Gastroenterol. 2011;17(17):2229–35.
5. Tran NQ, Malcontenti-Wilson C, Hammoud S, Millar I, Christophi C,
Muralidharan V. Hyperbaric oxygen therapy reduces the severity of
ischaemia, preservation and reperfusion injury in a rat model of liver
transplantation. HPB (Oxford). 2012;14(2):103–14.
6. Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E, Blanc JF, et al. Sorafenib
in advanced hepatocellular carcinoma. N Engl J Med. 2008;359(4):378–90.
7. Strumberg D, Richly H, Hilger RA, Schleucher N, Korfee S, Tewes M,
et al. Phase I clinical and pharmacokinetic study of the Novel Raf
kinase and vascular endothelial growth factor receptor inhibitor BAY
43–9006 in patients with advanced refractory solid tumors. J Clin Oncol.
2005;23(5):965–72.
8. Akaza H, Tsukamoto T, Murai M, Nakajima K, Naito S. Phase II study to
investigate the efficacy, safety, and pharmacokinetics of sorafenib in
Japanese patients with advanced renal cell carcinoma. Jpn J Clin Oncol.
2007;37(10):755–62.
9. Keating GM, Santoro A. Sorafenib: a review of its use in advanced
hepatocellular carcinoma. Drugs. 2009;69(2):223–40.
10. Peer CJ, Sissung TM, Kim A, Jain L, Woo S, Gardner ER, et al. Sorafenib is an
inhibitor of UGT1A1 but is metabolized by UGT1A9: implications of genetic
variants on pharmacokinetics and hyperbilirubinemia. Clin Cancer Res. 2012;
18(7):2099–107.
Submit your manuscript to a 
journal and beneﬁ t from:
7 Convenient online submission
7 Rigorous peer review
7 Immediate publication on acceptance
7 Open access: articles freely available online
7 High visibility within the ﬁ eld
7 Retaining the copyright to your article
    Submit your next manuscript at 7 springeropen.com
Kuroda et al. Surgical Case Reports  (2016) 2:4 Page 4 of 4
